Mr. Boris Djordjevic is the Chief Executive Officer of 199 Biotechnologies, a startup founded in 2023 focused on translating epigenetic reprogramming and gene therapies research into clinical products. Born in Belgium, Boris pivoted from medicine to entrepreneurship after being inspired by the SENS conference. Following a decade in China’s biotechnology sector, he established two longevity clinics in London. At 199 Biotechnologies, Boris leads efforts to develop a broad therapeutic pipeline aimed at extending healthspan and lifespan. His work emphasizes epigenetic reprogramming’s potential to address the root causes of aging and age-related diseases, potentially transforming patient care and outcomes. Boris is married with two children.